Data completeness
1/8 — Limited
DISOMER (dexbrompheniramine maleate) by Merck & Co.. Approved for nasal congestion due to the common cold, hay fever, other upper repiratory allergies helps decongest sinus opening and 5 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DISOMER is an oral syrup formulation of dexbrompheniramine maleate, a first-generation antihistamine indicated for nasal congestion, hay fever, and upper respiratory allergies. It works by blocking histamine receptors and reducing swelling of nasal passages to temporarily restore freer breathing and alleviate symptoms including runny nose, sneezing, itching, and watery eyes.
Pre-Launch
Pre-launch stage indicates significant investment in commercialization infrastructure; expect scaled-up field teams, regional marketing roles, and commercial planning positions to support market entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (8)
Worked on DISOMER at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.